William Blair Downgrades Quintiles (Q) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Wall Street sinks as bond yields rise, Walmart results disappoint
QuintilesIMS Announces Executive Leadership Changes
November 30, 2016 7:52 AM ESTRichard Staub III named president, Research & Development Solutions; Paul Spreen named executive vice president and chief customer officer; Thomas H. Pike to retire
DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- Quintiles IMS Holdings, Inc. (NYSE: Q) announced today the appointment of Richard Staub III, currently president of Novella Clinical, a Quintiles company, as well as the leader of QuintilesIMSs Global Functional Resourcing business and a member of the Research & Development Solutions Executive Committee, to serve as president of its Research & Development Solutions business unit. Staub brings more... More
